Clinical Trial Biorepository and Archiving Solutions

Global Clinical Trial Biorepository and Archiving Solutions Market to Reach US$6.3 Billion by 2030

The global market for Clinical Trial Biorepository and Archiving Solutions estimated at US$4.2 Billion in the year 2024, is expected to reach US$6.3 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Biorepository Services, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Archiving Solution Services segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.8% CAGR

The Clinical Trial Biorepository and Archiving Solutions market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Clinical Trial Biorepository and Archiving Solutions Market - Key Trends & Drivers Summarized

Why Are Biorepositories Essential for Clinical Trials?

Biorepositories play a fundamental role in clinical trials by providing secure storage and management of biological specimens, including blood, tissue, DNA, and RNA samples. These facilities ensure the integrity of biospecimens, enabling researchers to conduct high-quality, reproducible studies in drug development, personalized medicine, and biomarker discovery. The growing complexity of clinical trials, particularly in oncology, immunology, and rare diseases, has intensified the demand for advanced biobanking solutions. Cryopreservation and ultra-low temperature storage technologies are critical in maintaining the viability of biospecimens over extended periods, ensuring their usability for future research. Moreover, standardized protocols for sample collection, processing, and data management are enhancing the reliability of stored specimens, reducing variability in clinical research outcomes. With the shift toward precision medicine, biorepositories are becoming indispensable in linking genetic, proteomic, and metabolomic data to clinical phenotypes, facilitating deeper insights into disease mechanisms and treatment responses.

What Are the Advancements in Biorepository Technologies?

Innovations in biorepository technologies are significantly enhancing sample preservation, accessibility, and data integrity. Automated storage and retrieval systems are improving the efficiency of specimen management, minimizing the risk of human error and sample degradation. AI-powered biobanking software is enabling real-time tracking of biospecimens, ensuring compliance with regulatory guidelines and study protocols. The integration of blockchain technology in sample traceability is enhancing security and transparency in biorepository operations. Additionally, advancements in liquid biopsy storage solutions are allowing for the long-term preservation of circulating tumor DNA (ctDNA) and other biomarkers, supporting ongoing cancer research. Cloud-based biorepository management systems are facilitating seamless collaboration among global research institutions, enabling multi-center clinical trials to share critical biological data. As the scale and scope of clinical research continue to expand, next-generation biorepositories are playing an increasingly vital role in accelerating drug discovery and therapeutic innovation.

How Is the Market for Clinical Trial Biorepositories Evolving?

The demand for biorepository and archiving solutions is growing as clinical trial complexity increases and regulatory requirements become more stringent. Contract research organizations (CROs) and pharmaceutical companies are investing in state-of-the-art biobanking facilities to support large-scale trials and ensure sample integrity. The emergence of decentralized clinical trials (DCTs) is driving the need for remote biospecimen collection and digital sample tracking solutions. Moreover, ethical considerations and data privacy regulations, such as GDPR and HIPAA, are shaping the governance of biospecimen storage, emphasizing the need for secure and compliant biorepository infrastructure. Sustainability trends are also influencing biorepository operations, with laboratories adopting energy-efficient storage systems and eco-friendly cryopreservation technologies. As the demand for biobanked specimens rises in precision medicine and translational research, biorepositories are evolving into dynamic hubs for data-driven clinical innovation.

What’s Driving the Growth of the Clinical Trial Biorepository Market?

The growth in the clinical trial biorepository and archiving solutions market is driven by several factors, including increasing investments in precision medicine, the rise of biomarker-driven drug development, and expanding global clinical research initiatives. The demand for high-quality biospecimens is accelerating, fueled by the expansion of genomics, proteomics, and metabolomics research. Technological advancements in cryopreservation and automated biobanking systems are enhancing the efficiency and reliability of biospecimen storage. Regulatory frameworks mandating strict quality control and ethical guidelines for biorepository operations are further propelling market growth. Additionally, the increasing reliance on artificial intelligence for sample tracking and metadata analysis is optimizing the management of stored specimens. The proliferation of personalized medicine approaches is intensifying the need for well-characterized biospecimen repositories, driving sustained investments in biobanking infrastructure. As clinical trial designs become more complex, the role of biorepositories in accelerating drug discovery and regulatory approvals continues to expand, positioning the market for long-term growth.

SCOPE OF STUDY:

The report analyzes the Clinical Trial Biorepository and Archiving Solutions market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Service Type (Biorepository Services, Archiving Solution Services); Product Type (Preclinical Products, Clinical Products); Phase Type (Preclinical, Phase I, Phase II, Phase III, Phase IV)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• American Type Culture Collection (ATCC)
• Azenta U.S., Inc.
• BioStorage Technologies (Brooks)
• Celerion
• Cell&Co BioServices (Cryoport)
• Charles River Laboratories Intl., Inc.
• Cryoport, Inc.
• Hamilton Company
• IQVIA Holdings Inc.
• LabConnect
• Labcorp Drug Development
• Medpace Holdings, Inc.
• NMDP BioTherapies
• Precision for Medicine, Inc.
• Q2 Solutions
• Sartorius AG
• STC Biologics
• Thermo Fisher Scientific Inc. (Patheon)
• Veristat, LLC
• VWR International (Avantor)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.